Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2025-10-15 M&A Activity
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Notice of hearing to approve the proposed scheme 2 pages 186.2KB
M&A Activity Classification · 95% confidence The document is an ASX announcement dated 16 October 2025 regarding a notice of hearing to approve a proposed scheme of arrangement for Mayne Pharma Group Limited. It references a court hearing to approve the scheme, shareholder meetings, and procedural details for opposing the scheme. The content focuses on legal and procedural updates related to a merger or acquisition transaction rather than financial results, management changes, or regulatory certifications. The document is relatively short (3156 characters) and is an announcement of a legal proceeding related to a merger scheme, not the merger filing itself or a full report. Therefore, the most appropriate classification is 'M&A Activity' (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2025-10-15 English
Update on FIRB approval 1 page 84.6KB
M&A Activity Classification · 95% confidence The document is an ASX announcement providing an update on the Foreign Investment Review Board (FIRB) approval related to a proposed acquisition by way of a scheme of arrangement. It mentions the timing of the FIRB decision and the potential rescheduling of a court hearing. The content is an update on a regulatory approval process and acquisition timetable, not a full merger filing, financial report, or detailed investor presentation. The document is short (1855 characters) and serves as a regulatory announcement about the status of the acquisition process. Therefore, it fits best under the category of M&A Activity (TAR) as it relates to merger proposals and takeover bids.
2025-10-15 English
Notification of cessation of securities - MYX 4 pages 14.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights securities for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement to the ASX about changes in the company's issued securities, specifically the cessation of certain securities. This type of document corresponds to a notification about changes in capital structure or securities status rather than a full financial report or management discussion. Given the nature of the content, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation or lapse of securities.
2025-10-15 English
2025 Corporate Governance Statement and Appendix 4G 27 pages 946.2KB
Governance Information Classification · 95% confidence The document is titled '2025 Corporate Governance Statement' and is addressed as a release to the market in accordance with Listing Rules. It discusses the company's corporate governance practices, board composition, director independence, board meetings, and related governance policies. It references compliance with ASX Corporate Governance Council Principles and includes detailed governance information such as board duties, skills matrix, and director appointment processes. There is no indication that this is an announcement of a report publication or a brief summary; rather, it is a substantive governance report. The content aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. Therefore, the appropriate classification is CGR with high confidence.
2025-10-13 English
Annual Report to shareholders 84 pages 4.2MB
Regulatory Filings
2025-10-13 English
Notification of cessation of securities - MYX 4 pages 15.4KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the expiry and cessation of certain securities (performance rights and options) for Mayne Pharma Group Limited. It includes specific ASX security codes, numbers of securities ceased, reasons for cessation, and updated issued capital figures. This is a regulatory announcement related to changes in the company's issued capital due to expiry of securities, consistent with a Share Issue/Capital Change announcement. The document is not a full financial report, earnings release, or management discussion, but a formal notification of capital changes. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change). The document length and content support a high confidence in this classification.
2025-10-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.